Benzinga | Jan 19, 2021 08:28AM EST

Raymond James Maintains Strong Buy on Acceleron Pharma, Raises Price Target to $160

Raymond James maintains Acceleron Pharma (NASDAQ:XLRN) with a Strong Buy and raises the price target from $155 to $160.